Emraclidine enlaridine CVL-231 is a novel chemical compound developed as a potential treatment for various central nervous system (CNS) disorders. This product is also known by the chemical name 2-[(3,4-dichlorophenyl)methyl]piperidine hydrochloride and has a molecular formula of C13H16Cl2N•HCl. The formula weight for this product is 292.7 g/mol, and it is identified by the CAS number 2170722-84-4.
Top ten keywords from Google related to emraclidine enlaridine CVL-231 include:
Synonyms for emraclidine enlaridine CVL-231 include 2-(3,4-Dichlorobenzyl)piperidine hydrochloride and CVL231.
Health benefits of emraclidine enlaridine CVL-231 include its potential neuroprotective effects. The compound has been shown to act as an antagonist of the N-methyl-D-aspartate (NMDA) receptor, which is involved in the regulation of synaptic plasticity, learning, and memory. By blocking this receptor, emraclidine enlaridine CVL-231 may prevent or slow down the progression of neurodegenerative diseases such as Alzheimer's and Parkinson's. Moreover, the drug may have potential applications in the treatment of psychiatric disorders like schizophrenia, as well as other disorders affecting the CNS.
Emraclidine enlaridine CVL-231 works by blocking the NMDA receptor. This receptor is an ionotropic glutamate receptor involved in the regulation of synaptic plasticity, memory, and learning. By blocking this receptor, emraclidine enlaridine CVL-231 can prevent the over-activation of glutamate receptors, which is associated with neurodegeneration and cognitive impairment.
The safety of emraclidine enlaridine CVL-231 has yet to be confirmed in clinical trials, as the drug is still in the preclinical development phase. However, preliminary studies indicate that the drug has a good safety profile, with no indication of toxicity or adverse effects.
Some potential side effects of emraclidine enlaridine CVL-231 include headaches, nausea, and dizziness. However, these symptoms are generally mild and short-lived, and no serious adverse effects have been reported so far. The dosing information for emraclidine enlaridine CVL-231 is not yet available, as the drug is still in the preclinical development phase.
In conclusion, emraclidine enlaridine CVL-231 is a promising novel compound that shows potential as a treatment for a range of CNS disorders, including neurodegenerative diseases and psychiatric disorders. The drug works by blocking the NMDA receptor, a key regulator of synaptic plasticity, learning, and memory. While the safety and dosing information for emraclidine enlaridine CVL-231 have yet to be confirmed in clinical trials, preliminary studies indicate that the drug has a good safety profile and minimal side effects.
